

Please type a plus sign (+) in the box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) SHEET <input type="text" value="1"/> OF <input type="text" value="5"/>		<i>Complete if Known</i>	
		Application Number	TO BE ASSIGNED
		Filing Date	March 29, 2001
		First Named Inventor	Michael FUNG
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	TNX 98-2-01

JCB97 U.S. PTO
 09/02/255
 03/29/01

U.S. PATENT DOCUMENTS					
Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number	Kind Code (if known)			
AN	5,856,297	B1	Fearon, et al.	01-05-1999	—
	5,456,909	B1	March, Jr. et al.	10-10-1995	—
	5,858,969	B1	Marsh, Jr. et al.	01-12-1999	—
	5,679,546	B1	Ko, et al.	10-21-1997	—
	5,856,300	B1	Rittershaws, et al.	01-05-1999	—
	5,624,837	B1	Fodor, et al.	04-29-1997	—
	5,627,264	B1	Fodor, et al.	05-06-1997	—
	5,853,722	B1	Rollins, et al.	12-29-1998	—
	5,851,528	B1	Ko, et al.	12-22-1998	—

FOREIGN DOCUMENTS							
Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (if known)				
AN	WO	95/29697		Evans, et al.	11-09-1995	—	N/A

Examiner Signature	<i>Ann DeClaw</i>	Date Considered	11-15-02
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside the box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET

2

OF

5

Complete if Known

Application Number **TO BE ASSIGNED**

Filing Date **March 29, 2001**

First Named Inventor **Michael FUNG**

Group Art Unit

Examiner Name

Attorney Docket Number

TNX 98-2-01

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T ²
dy	C1	Klohs, Wayne D., et al., "Inhibitors of Tyrosine Kinase", <i>Current Opinion in Oncology</i> , Vol. 9, pp. 562-568 (1997).	
	C2	Stadel, Jeffrey, et al., "Orphan G Protein-Coupled Receptors – A Neglected Opportunity for Pioneer Drug Discovery", <i>TiPS</i> , Vol. 18, pp. 430-437 (1997).	
	C3	Strawn, Laurie, et al., "FLK-1 as Target Tumor Growth Inhibition", <i>Cancer Research</i> , Vol. 56, pp. 3540-3545 (1996).	
	C4	Abhijit, Ray, et al., "Thrombin Receptor: A Novel Target for Antiplatelet Drug Development", <i>Thrombosis Research</i> , Vol. 87, No. 1, pp. 37-50 (1997).	
	C5	Sato, Toshiro, et al., "A New Method for Studying a Binding of Human IgE to CD23 and the Inhibition of this Binding", <i>Journal of Immunological Methods</i> , Vol. 209, pp. 59-66 (1997).	
	C6	Bertozzi, C. R. Carolyn, et al., "An ELISA for Selectins Based on Binding to a Physiological Ligand" <i>Journal of Immunological Methods</i> , Vol. 203, pp. 157-165 (1997).	
	C7	Gao, Jingbo, et al., "An Enzyme-Linked Immunosorbent Assay to Identify Inhibitors of Activation of Platelet Intergrin $\alpha_{IIb}\beta_3$ " <i>Journal of Immunological Methods</i> , Vol. 181, pp. 55-64 (1995).	
	C8	Wilson, Anne B., et al., "A Competitive Inhibition ELISA for the Quantification of Human Interferon- γ ", <i>Journal of Immunological Methods</i> , Vol. 162, pp. 247-255 (1993).	
✓	C9	Pascual, Manuel, et al., "A Monoclonal Antibody Which Blocks the Function of Factor D of Human Complement", <i>Journal of Immunological Methods</i> , Vol. 127, pp. 263-269 (1990).	
✓	C10	Pascual, Manuel, et al., "Inhibition of Complement Alternative Pathway in Mice with Fab Antibody to Recombinant Adipsin/Factor D", <i>Euro. J. Immunol.</i> , Vol. 23, pp. 1389-1392 (1993).	
✓	C11	Omer, Charles, et al., "CA ₁ A _{2x} -Competitive Inhibitors of Farnesyltransferase as Anti-Cancer Agents", <i>TiPS</i> , Vol. 18, pp. 437-443 (1997).	
Examiner Signature	Amy D. Elmore		Date Considered 11/15/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside the box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	TO BE ASSIGNED
(Use as many sheets as necessary)		Filing Date	March 29, 2001
		First Named Inventor	Michael FUNG
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	TNX 98-2-01
SHEET	3	OF	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
an	C12	Lam, Kits, et al., "Application of Combinatorial Library Methods in Cancer Research and Drug Discovery", <i>Anti-Cancer Drug Design</i> , Vol. 12, pp. 145-167 (1997).	
✓	C13	Tanhehco, E. J., et al., "The Anti-Factor D Antibody, MAb 166-32, Inhibits the Alternative Pathway of the Human Complement System", <i>Transplantation Proceedings</i> , Vol. 31, pp. 2168-2171 (1999).	
	C14	Houghten, R. A., et al., "The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides", <i>Biotechniques</i> , Vol. 13, No. 3, pp. 412-421 (1992).	
	C15	Huber-Lang, Markus, et al., "Role of C5a in Multiorgan Failure During Sepsis" <i>Journal of Immunology</i> , Vol. 166, pp. 1193-1198, (2001).	
	C16	Sim, R. B., et al., "Serine Proteases of the Complement System", <i>Biochemical Society Transactions</i> , Vol. 28, Pt.5, pp. 545-550 (2000).	
✓	C17	Kroshus, T. J., et al., "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-to-Human Xenotransplantation", <i>Transplantation</i> , Vol. 60, pp. 1194-1202 (1995).	
✓	C18	Volkanakis, John E., et al., "Complement Factor D, A Novel Serine Protease", <i>Protein Science</i> , Vol. 5, pp. 553-564 (1996).	
✓	C19	Niemann, Marilyn A., et al., "The Use of Monoclonal Antibodies as Probes of the Three Dimensional Structure of Human Complement Factor D", <i>J. Immunol.</i> , Vol. 132, No. 2, pp. 809-815 (1984).	
✓	C20	Evans, Mark J., et al., "Rapid Expression of an Anti-Human C5 Chimeric Fab Utilizing a Vector that Replicates in COS and 293 Cells, <i>J. Immunol.</i> Vol. 184, pp. 123-138 (1995).	
✓	C21	Rabinovici, Reuven, et al., "Role of Complement in Endotoxin/Platelet-Activating: Factor-Induced Lung Injury", <i>J. Immunol.</i> , Vol 149, No. 5, pp. 1744-1750 (1992).	
✓	C22	White, R. Tyler, et al., "Human Adipsin is Identical to Complement Factor D and is Expressed at High Levels in Adipose Tissue", <i>J. Biology</i> , Vol. 267, No. 13, pp. 9210-9213 (1992).	
Examiner Signature	[Signature]		Date Considered 11-15-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside the box.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET

4

OF

5

Complete if Known

Application Number **TO BE ASSIGNED**

Filing Date **March 29, 2001**

First Named Inventor **Michael FUNG**

Group Art Unit

Examiner Name

Attorney Docket Number

TNX 98-2-01

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T 2
✓	C23	Narayana, Sthanam, et al., "Structure of Human Factor D: A Complement System Protein at 20° Resolution", <i>J. Mol. Biol.</i> , Vol. 235, pp. 695-708 (1994).	
✓	C24	Rider, Christine S., et al., "Blockade of C5a and C5b-9 Generation Inhibits Leukocyte and Platelet Activation During Extracorporeal Circulation", <i>J. Clin. Invest.</i> , Vol. 96, pp. 1564-1572 (1995).	
✓	C25	Lesavre, Phillippe H., et al., "Mechanism of Action of Factor D of the Alternative Complement Pathway", <i>J. Exp. Med.</i> , Vol. 148, pp. 1498-1509 (Dec. 1978).	
✓	C26	Homeister, Jonathon, et al., "Soluble Complement Receptor Type I Prevents Human Complement-Medicated Damage of the Rabbit Isolated Heart", <i>The Journal of Immunology</i> , Vol. 150, No. 3, pp. 1055-1064 (1993).	
✓	C27	Amsterdam, Ezra A., et al., "Limitation of Reperfusion Injury by a Monoclonal Antibody to C5a During Myocardial Infarction in Pigs", <i>Am. J. Physiol.</i> , Vol. 268, pp. H448-H457 (1995).	
✓	C28	Wang, Yi, et al., "Anti-C5 Monoclonal Antibody Therapy Prevents Collagen-Induced Arthritis and Ameliorates Established Disease", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 8955-8959 (1995).	
✓	C29	Weismann, Harlan F., et al., "Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis", <i>Science</i> , Vol. 249, pp. 146-151 (1990).	
✓	C30	Mulligan, Michael S., et al., "Protective Effects of Soluble CR1 in Complement and Neutrophil-Medicated Tissue Injury", <i>J. Immunol.</i> , Vol 148, No. 5, pp. 1479-1485 (1992).	
✓	C31	Morgan, B. P., et al., "Clinical Complementology: Recent Progress and Future Trends", <i>European Journal of Clinical Investigation</i> , Vol. 24, pp. 219-228 (1994).	
✓	C32	Wang, Y., et al., "Amelioration of Lupus-Like Autoimmune Disease in NZB/W F ₁ Mice After Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5", <i>Natl. Acad. Sci. USA</i> , Vol. 93, pp. 8563-8568 (1996).	
✓	C33	Holers, Michael V., et al., "Complement", In: <u>Host Defense Mechanism and Inflammation</u> , Chapter 24, pp. 363-391.	
Examiner Signature	 Amy DeChenne		Date Considered 11-15-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside the box.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET

5

OF

5

Complete if Known

Application Number **TO BE ASSIGNED**

Filing Date **March 29, 2001**

First Named Inventor **Michael FUNG**

Group Art Unit

Examiner Name

Attorney Docket Number **TNX 98-2-01**

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T 2
ADV	C34	Volonakis, et al., "Complement Enzymes", In: <u>The Human Complement System in Health & Disease</u> , Chapter 4, Ed., J. Volonakis & M. M. Frank.	
✓	C35	Fung, M., et al., "Inhibition of Complement, Neutrophil, and Platelet Activation by an Anti-Factor D Antibody During Extracorporeal Circulation", Presented in the 18 th Annual Houston Conference on Biomedical Engineering Research, Houston, Texas, Feb. 10-11, 2000, (Abstract).	
✓	C36	Undar, A., et al., "Novel Anti-Factor D Monoclonal Antibody Inhibits Complement, Neutrophil, and Platelet Activation in a Simulated Pediatric Cardiopulmonary Bypass Circuit., Presented in the 46 th Annual Conference of the American Society for Artificial Internal Organs, New York, N.Y., June 28- July 1, 2000, (Abstract).	
✓	C37	Loubser, P. G., et al., "Inhibition of Complement, Neutrophil, Platelet, and Cytokine Activation by an Anti-Factor D Antibody During Extracorporeal Circulation., Presented in <i>The American Society of Anesthesiologists 2000 Annual Meeting</i> , San Francisco, California, October 14-18. 2000, (Poster Presentation).	
Examiner Signature			Date Considered 11-15-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.